{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.71","statisticalComment":"Two-sided significance level = 0.05","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18","upperLimit":"38","value":"27"},{"groupId":"OG001","lowerLimit":"20","upperLimit":"41","value":"29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"description":"Pathologic Complete Response (pCR) is evaluated after surgery and is based on the pathology review of the submitted surgical specimen. Pathologic Complete Response occurs if the pathologist determines that the resected esophageal specimen, accompanying lymph nodes, and surgical margins are all free of tumor.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy with concurrent trastuzumab, paclitaxel, and carboplatin followed by surgery followed by maintenance trastuzumab","id":"OG000","title":"Chemoradiation and Trastuzumab"},{"description":"Radiation therapy with concurrent paclitaxel and carboplatin followed by surgery","id":"OG001","title":"Chemoradiation"}],"paramType":"NUMBER","populationDescription":"Eligible participants who had surgery","reportingStatus":"POSTED","timeFrame":"At the time of surgery, 5-8 weeks after completion of radiation therapy.","title":"Percentage of Participants With Pathologic Complete Response at Surgery","type":"SECONDARY","unitOfMeasure":"percentage of participants"}